Steve Harr
Steve Harr is the co-founder and CEO at Sana. He founded Sana, which went public and where he continues to lead.
Sana Biotechnology Appoints Brian Piper as CFO; Aptevo CEO Marvin White to Step Down in April; Violett Names Scott Kushino CEO
Brian Piper was appointed CFO and executive vice president at Sana Biotechnology, while Marvin White will step down as Aptevo CEO in April, succeeded by COO Jeff Lamothe. Additionally, Scott Kushino became CEO of Seattle startup Violett, and several other leadership changes occurred across Seattle and New York tech companies.
Sana Biotechnology Opens $80M Manufacturing Facility in Bothell to Scale Cancer and Gene Therapy Production
Sana Biotechnology inaugurated its new 80,000 square-foot manufacturing facility in Bothell, Washington, dedicated to producing its proprietary cancer drug program and future therapies. The company, known for its gene-editing technology and multiple drugs in human trials including for cancer, autoimmune diseases, and type 1 diabetes, sees this expansion as a key step in advancing scalable cell and gene therapies.
Affini-T Therapeutics launched by Fred Hutch scientists including Juno co-founder Philip Greenberg to develop engineered TCR cancer therapies
Affini-T Therapeutics, founded by Fred Hutch scientists including Philip Greenberg (a Juno co-founder), Aude Chapuis and Thomas Schmitt, launched to develop T cell receptor (TCR) cancer immunotherapies that add engineered CD8 co-receptors and other gene edits. The Boston-headquartered company, led by CEO Jak Knowles, was unveiled at the J.P. Morgan Health Care Conference and will operate a research lab in Seattle.
Organizations
-
Sana Biotechnology Co-founder and CEO · current
